



Attorney Docket No.: 10038.200-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Svendsen et al.

Confirmation No: 4049

Serial No.: 09/873,075

Group Art Unit: 1633

Filed: June 1, 2001

Examiner: To Be Assigned

For: Cutinase Variants

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Transmittal of Certified Copy of Priority Application(s)
2. Certified Copy of Priority Application(s)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on February 4, 2002.

Julie Tabarovsky  
(name of person mailing paper)

*Julie Tabarovsky*  
(signature of person mailing paper)

#11  
RECEIVED  
FEB 22 2002  
TECH CENTER 1600/2900



Attorney Docket No.: 10038.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Svendsen et al.

Confirmation No: 4049

Serial No.: 09/873,075

Group Art Unit: 1633

Filed: June 1, 2001

Examiner: To Be Assigned

For: Cutinase Variants

**TRANSMITTAL OF CERTIFIED COPY OF PRIORITY APPLICATION(S)**

Commissioner for Patents  
Washington, DC 20231


Sir:

Attached please find four certified copies of the foreign application from which priority is claimed for this case:

1. Country: Denmark  
Application Number: PA 2000 00861  
Filing Date: June 2, 2000
2. Country: Denmark  
Application Number: PA 2000 01577  
Filing Date: October 23, 2000
3. Country: Denmark  
Application Number: PA 2000 01772  
Filing Date: November 24, 2000
4. Country: Denmark  
Application Number: PA 2001 00100  
Filing Date: January 19, 2001

Respectfully submitted,

Date: February 4, 2002

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

RECEIVED

FEB 22 2002

TECH CENTER 1600/2900



# Kongeriget Danmark

Patent application No.: PA 2000 00861

Date of filing: 02 June 2000

Applicant: Novozymes A/S  
Krogshøjvej 36  
DK-2880 Bagsværd

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification and claims as filed with the application on the filing date indicated above.

By assignment dated 17 Nov 2000 and filed on 01 Dec 2000, the application has been assigned to Novozymes A/S.



Patent- og  
Varemærkestyrelsen  
Erhvervsministeriet



TAASTRUP 08 June 2001

Inge-Lise Sørensen  
Head Clerk

02 JUNI 2000

## CUTINASE VARIANTS

Modtaget

## FIELD OF THE INVENTION

The present invention relates to a cutinase variant, more particularly to a cutinase variant having improved thermostability. The invention also relates to a DNA sequence encoding the variant, a vector comprising the DNA sequence, a transformed host cell harboring the DNA sequence or the vector, to a method of producing the variant, and to use of the variant.

## BACKGROUND OF THE INVENTION

Cutinases are lipolytic enzymes capable of hydrolyzing the substrate cutin. Cutinases are known from various fungi (P.E. Kolattukudy in "Lipases", Ed. B. Borgström and H.L. Brockman, Elsevier 1984, 471-504). The amino acid sequence and the crystal structure of a cutinase of *Fusarium solani pisi* have been described (S. Longhi et al., Journal of Molecular Biology, 268 (4), 779-799 (1997)). The amino acid sequence of a cutinase from *Humicola insolens* has also been published (US 5,827,719).

A number of variants of the cutinase of *Fusarium solani pisi* have been published: WO 94/14963; WO 94/14964; WO 00/05389; Appl. Environm. Microbiol. 64, 2794-2799, 1998; Proteins: Structure, Function and Genetics 26, 442-458, 1996; J. of Computational Chemistry 17, 1783-1803, 1996; Protein Engineering 6, 157-165, 1993; Proteins: Structure, Function, and Genetics 33, 253-264, 1998; J. of Biotechnology 66, 11-26, 1998; Biochemistry 35, 398-410, 1996; Chemistry and Physics of Lipids 97, 181-191, 1999; Proteins: Structure, Function, and Genetics 31, 320-333, 1998; Biochimica et Biophysica Acta 1441, 185-196, 1999; Appl. Environm. Microbiol. 64, 316-324, 1998; BioTechniques 27, 1102-1108, 1999.

Fungal cutinases may be used in the enzymatic hydrolysis of cyclic oligomers of poly(ethylene terephthalate), e.g. in the finishing of yarn or fabric from poly(ethylene terephthalate) fibers (WO 97/27237). However, it is desirable to improve the thermostability of known fungal cutinases to allow a higher process temperature.

## SUMMARY OF THE INVENTION

The inventors have found certain variants of fungal cutinases having improved thermostability. The variants comprise substitution of one or more amino acid residues at positions corresponding to Q1, L2, A4, G8, S11, N15, N44, S48, H49, 5 L66, A88, N91, S116, S119, G120, A130, Q139, 7164, I169, L174, R189 and/or the N-terminal extension AAVDSNHTPAVPELVAR. The variants may optionally comprise additional alterations at other positions.

The invention also provides a DNA sequence encoding the variant, an expression vector comprising the DNA sequence, a transformed host cell harboring the 10 DNA sequence or the expression vector, a method of producing the variant, processes using the variant and a detergent composition comprising the variant.

Further, the invention provides a method of producing cutinase variants by introducing amino acid alterations (substitution, deletion or insertion) at one or more of the indicated positions or in a region comprising such position, and selecting variants with 15 improved thermostability. The alterations may be made, e.g., by localized random mutagenesis or by site-directed mutagenesis.

## DETAILED DESCRIPTION OF THE INVENTION

### Fungal cutinase

The parent cutinase is a fungal cutinase, such as a filamentous fungal cutinase, e.g. native to a strain of *Humicola* or *Fusarium*, specifically *H. insolens* or *F. solani pisi*, more specifically *H. insolens* strain DSM 1800. 20

The amino acid sequence of the cutinase of *H. insolens* strain DSM 1800 and the DNA sequence encoding it are shown as SEQ ID NO: 2 and SEQ ID NO: 1 of US 5,827,719. The numbering system used herein for the *H. insolens* cutinase is 25 based on the mature peptide, as shown in said SEQ ID NO: 2.

The amino acid sequence of the cutinase of *F. solani pisi* is shown as the mature peptide in Fig. 1D of WO 94/14964. The numbering system used herein for the *F. solani pisi* cutinase is that used in WO 94/14964; it includes the pro-sequence shown in said Fig. 1D; thus, the mature cutinase is at positions 16-214.

30 The parent cutinase may have an amino acid sequence which is at least 50 % (particularly at least 70 % or at least 80 %) homologous to the cutinase of *H. inso-*

*lens* strain DSM 1800. The parent cutinase may particularly be one that can be aligned with the cutinase of *H. insolens* strain DSM 1800.

### Nomenclature for amino acids and alterations

The specification and claims refer to amino acids by their one-letter codes. A particular amino acid in a sequence is identified by its one-letter code and its position, e.g. Q1 indicates Gln (glutamine at position 1, i.e. at the N-terminal).

The nomenclature used herein for defining substitutions is basically as described in WO 92/05249. Thus, S11T indicates substitution of S (Ser) at position 11 with T (Thr). Q1C/L indicates substitution of Q (Gln) with C (Cys) or L (Leu).

### 10 Homology and alignment

For purposes of the present invention, the degree of homology may be suitably determined according to the method described in Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-45, with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1. The determination may be done by means of a computer program known such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711).

Two given sequences can be aligned according to the method described in Needleman (*supra*) using the same parameters. This may be done by means of the GAP program (*supra*).

The homology between the parent cutinase and the cutinase variant may be above 80 %, e.g. above 85 % or above 90 %, particularly above 95 %.

### Specific substitutions

The variants may particularly comprise one or more substitutions corresponding to the following in the *H. insolens* cutinase (*H. insolens* cutinase numbering): Q1C/L, L2K/Q/V, A4V, G8D, S11T, N15D, A16T, N44D, S48E/K, H49Y, L66I, A88H/L/V, N91H, S116K, S119P, G120D, A130V, Q139R, T164S, I169A/G/V, L174F and/or R189A/H/V.

More specifically, the cutinase variant may include the following such substitutions or combinations of substitutions:

S48E +A88H +N91H +R189V
Q1L +L2K +G8D +N15D
N44D +A130V
Q1C +L2V +G120D
A88L +R189A
S48E +L66I +A88L +I169A +R189H
A88V +S116K +S119P +Q139R +I169V +R189V
A88V +R189A
S48K +A88H +I169G +R189H
Q1L +L2Q +A4V +S11T
T164S
L174F
H49Y
Q1L +L2K +G8D +N15D +S48E +A88H +N91H +R189V
Q1L +L2K +G8D +N15D +N44D +A130V
Q1L +L2K +G8D +N15D +S48E +A88H +N91H +A130V +R189V
G8D +N15D +A16T
A130V
Q1C +L2V

### Optional substitutions

In addition to the substitutions described above, the cutinase variant may optionally include one or more other amino acid alterations, particularly substitution of one or more amino acid residues corresponding to the following in the *H. insolens* cutinase (*H. insolens* cutinase numbering): Q1, L2, E6, E10, S11, A14, N15, F24, L46, E47, R51, D63, L138 and/or E179, more particularly one or more substitutions corresponding to Q1P, L2V, E6Q, E10Q, S11C, A14P, N15T, F24Y, L46I, E47K, R51P, D63N, L138I and/or E179Q.

More specifically, the cutinase variant may include the following such substitutions or combinations of substitutions:

R51P

E6N/Q+ L138I

A14P+ E47K

E47K

E179N/Q

E6N/Q+ E47K+ R51P

A14P+ E47K+ E179N/Q

E47K+ E179N/Q

5 E47K+ D63N

E6N/Q+ E10N/Q+ A14P+ E47K+ R51P+ E179N/Q

E6N/Q+ A14P+ E47K+ R51P+ E179N/Q

Q1P+ L2V+ S11C+ N15T+ F24Y+ L46I+ E47K

### Use of cutinase variant

10 The cutinase variant of the invention may be used, e.g., for the enzymatic hydrolysis of cyclic oligomers of poly(ethylene terephthalate), such as cyclic tri(ethylene terephthalate), abbreviated as c3ET.

In particular, this may be used to remove such cyclic oligomers from polyester containing fabric or yarn by treating the fabric or yarn with the cutinase variant, optionally  
 15 followed by rinsing the fabric or yarn with an aqueous solution having a pH in the range of from about pH 7 to about pH 11. The treatment of polyester is conveniently carried out above the glass transition temperature of c3ET (about 55°C) and below the glass transition temperature of polyester (about 70°C). Thus, the treatment may suitably be carried out at 50-80°C, e.g. at 60-75°C. The process may be carried out in analogy  
 20 with WO 97/27237.

The cutinase variant may be used to treat polyester-containing textile. e.g. PET (polymer of ethyleneglycol and terephthalic acid), P3GT (polymer of 1,3-propanediol and terephthalic acid) or a polyester/cotton blend. The treatment may provide benefits to the polyester textile such as improved wear and comfort, increased water permeability, re-  
 25 duced antistatic behavior, improve handle and softness, changed redeposition characteristics and/or color clarification.

The cutinase variant may be used to improve the functional finish of a PET-containing yarn or fabric by a treatment with the cutinase variant, followed by a treatment with a finishing agent such as a softener, an anti-crease resin, an anti-  
 30 static agent, an anti-soiling agent or agents to impair wrinkle-free, permanent press or fire resistance effects. The treatment with the cutinase variant may increase the number of functional groups in the surface, and this can be used to attach the func-



tional finish. Examples of finishing agents are described in "SENSHOKU SIAGEKAKO BENRAN" published 1998-10-15 by Nihon Seni Sentaa KK.

The cutinase variant of the invention is also useful in detergents, where it may be incorporated to improve the removal of fatty soiling, as described in WO 94/03578  
5 and WO 94/14964. The addition of the cutinase variant to laundry detergent may reduce malodor from cloth which is accumulated during several wash/wear-cycles.

The cutinase variant may also be used for degradation and recycling of polyester such as polycaprolactone (PCL), poly-ethyleneglycol-terephthalate (PET), polylactic acid, polybutylenesuccinate, and poly(hydroxybutiric acid)-co-(hydroxyvaleric acid), e.g.  
10 film and bottles, e.g. as described in JP-A 5-344897.

The cutinase variant may also be used for other known applications of lipases and cutinases, for example, in the baking industry (e.g. as described in WO 94/04035 and EP 585988), in the papermaking industry (e.g. for pitch removal, see EP 374700), and in the leather, wool and related industries (e.g. for degreasing of  
15 animal hides, sheepskin or wool), and for other applications involving degreasing/defatting. It may be used in immobilized form in the fat and oil industry, as a catalyst in organic synthesis (e.g. esterification, transesterification or ester hydrolysis reactions).

### **Dyeing polyester**

20 The invention provides a process for dyeing polyester fabric or yarn. In this process, the fabric or yarn is first treated with a cutinase, e.g. 12-48 hours at 50-70°C or 65-70°C, pH 7-10, followed by dyeing with dye, e.g. a reactive dye, a disperse dye or a cationic dye. The reactive dye may be one that reacts with OH or COOH groups, e.g. having the structure Chromophore-NHPh-SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OSO<sub>3</sub>Na. The dyeing may be con-  
25 ducted at 40-80°C, e.g. for 20-60 minutes.

The cutinase may be a thermostable cutinase having a thermal denaturation temperature, T<sub>d</sub>, at pH 8.5 which is at least 5° higher than the parent cutinase, e.g. 7-10° higher, e.g. a value of 65°C or higher. The measurement may be made by DSC as described in an Example of this specification.

**Surfactant**

In the treatment of fabric or yarn, a conventional wetting agent and/or a dispersing agent may be used to improve the contact with the enzyme. The wetting agent may be a nonionic surfactant, e.g. an ethoxylated fatty alcohol. A very useful wetting agent is an ethoxylated and propoxylated fatty acid ester such as Berol 087 (product of Akzo Nobel, Sweden).

The dispersing agent may suitably be selected from nonionic, anionic, cationic, ampholytic or zwitterionic surfactants. More specifically, the dispersing agent may be selected from carboxymethylcellulose, hydroxypropylcellulose, alkyl aryl sulfonates, long-chain alcohol sulfates (primary and secondary alkyl sulfates), sulfonated olefins, sulfated monoglycerides, sulfated ethers, sulfosuccinates, sulfonated methyl ethers, alkane sulfonates, phosphate esters, alkyl isothionates, acylsarcosides, alkyltaurides, fluorosurfactants, fatty alcohol and alkylphenol condensates, fatty acid condensates, condensates of ethylene oxide with an amine, condensates of ethylene oxide with an amide, sucrose esters, sorbitan esters, alkylamides, fatty amine oxides, ethoxylated monoamines, ethoxylated diamines, alcohol ethoxylate and mixtures thereof. A very useful dispersing agent is an alcohol ethoxylate such as Berol 08 (product of Akzo Nobel, Sweden).

**20 Methods for preparing cutinase variants**

The cutinase variant of the invention can be prepared by methods known in the art, e.g. as described in WO 94/14963 or WO 94/14964 (Unilever). The following describes methods for the cloning of cutinase-encoding DNA sequences, followed by methods for generating mutations at specific sites within the cutinase-encoding sequence.

**Cloning a DNA sequence encoding a cutinase**

The DNA sequence encoding a parent cutinase may be isolated from any cell or microorganism producing the cutinase in question, using various methods well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the cutinase to be studied. Then, if the amino acid sequence of the cutinase is known, labeled oligonucleotide probes may be synthesized and used to identify cuti-

nase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labeled oligonucleotide probe containing sequences homologous to another known cutinase gene could be used as a probe to identify cutinase-encoding clones, using hybridization and washing conditions of lower stringency.

5 Yet another method for identifying cutinase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming cutinase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for cutinase (*i.e.* maltose), thereby allowing clones expressing the cutinase to be identified.

10 Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, *e.g.* the phosphoroamidite method described S.L. Beaucage and M.H. Caruthers, (1981), Tetrahedron Letters 22, p. 1859-1869, or the method described by Matthes et al., (1984), EMBO J. 3, p. 801-805. In the phosphoroamidite method, oligonucleotides are synthesized, *e.g.* in an  
15 automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the frag-  
20 ments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al., (1988), Science 239, 1988, pp. 487-491.

#### **Construction of cutinase variant**

25 A cutinase variant may be obtained by site-directed mutagenesis at selected positions or by localized random mutagenesis, *i.e.* by introduction of random amino acid residues in selected positions or regions of the parent enzyme, *e.g.* as described in WO 95/22615. A preferred method is to use doped or spiked oligonucleotides for the mutagenesis.

30 The selected positions may be one more of those described above, and the selected region may be one comprising one or more of these positions. Some particular examples are:

**A. Spiked oligo shuffling:**

	Library S1:	44, 46, 48, 51, 55
	Library S2:	48, 66, 88, 91, 119, 169, 189
	Library S3:	26, 66, 70, 139, 167, 168, 169, 174
5	Library S4:	4, 5, 6, 33, 34
	Library S5:	6, 7, 8, 9, 55, 56, 57

**B. Doped libraries:**

	Library 1:	42-52
	Library 2:	59-77
10	Library 3:	116-122
	Library 4:	1-16
	Library 5:	69, 70, 73
	Library 6:	140-145
	Library 7:	161, 162, 164-174

**15 Site-directed mutagenesis**

Once a cutinase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites. In a specific method, a single-stranded gap of DNA, the cutinase-encoding sequence, is created in a vector carrying the cutinase gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al., (1984), *Biotechnology* 2, p. 646-639.

25 US 4,760,025 discloses the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Another method for introducing mutations into cutinase-encoding DNA sequences is described in Nelson and Long, (1989), *Analytical Biochemistry* 180, p. 147-151. It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the

30

primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.

### Expression of cutinase variants

5        According to the invention, a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

### 10 Expression vector

The recombinant expression vector carrying the DNA sequence encoding a cutinase variant of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. The vector may be one which, when  
15 introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated. Examples of suitable expression vectors include pMT838.

### Promoter

In the vector, the DNA sequence should be operably connected to a suitable  
20 promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the DNA sequence encoding a cutinase variant of the invention, especially in a bacterial host,  
25 are the promoter of the *lac* operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis*  $\alpha$ -amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens*  $\alpha$ -amylase (*amyQ*), the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes etc. For transcription in a fun-  
30 gal host, examples of useful promoters are those derived from the gene encoding A.

*oryzae* TAKA amylase, the TPI (triose phosphate isomerase) promoter from *S. cerevisiae* (Alber et al. (1982), J. Mol. Appl. Genet 1, p. 419-434, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral  $\alpha$ -amylase, *A. niger* acid stable  $\alpha$ -amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae*  
5 triose phosphate isomerase or *A. nidulans* acetamidase.

### Expression vector

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the  $\alpha$ -amylase variant of the invention. Termination and polyadenylation sequences may suitably be derived from the same  
10 sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

15 The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker  
20 giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g. as described in WO 91/17243.

The procedures used to ligate the DNA construct of the invention encoding a cutinase variant, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication,  
25 are well known to persons skilled in the art (cf., for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989).

### Host Cells

The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in  
30 the recombinant production of a cutinase variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveni-

ently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional  
5 methods, e.g. by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

The cell of the invention may be a cell of a higher organism such as a mammal or an insect, particularly a microbial cell, e.g. a bacterial or a fungal (including  
10 yeast) cell.

Examples of suitable bacteria are Gram positive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*, or gramnegative bacteria such as *E.coli*. The  
15 transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known *per se*.

The yeast organism may favorably be selected from a species of *Saccharomyces* or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*.

20 The host cell may also be a filamentous fungus e.g. a strain belonging to a species of *Aspergillus*, particularly *Aspergillus oryzae* or *Aspergillus niger*, or a strain of *Fusarium*, such as a strain of *Fusarium oxysporum*, *Fusarium graminearum* (in the perfect state named *Gibberella zeae*, previously *Sphaeria zeae*, synonym with *Gibberella roseum* and *Gibberella roseum* f. sp. *cerealis*), or *Fusarium sulphureum* (in  
25 the prefect state named *Gibberella puricaris*, synonym with *Fusarium trichothecioides*, *Fusarium bactridioides*, *Fusarium sambucinum*, *Fusarium roseum*, and *Fusarium roseum* var. *graminearum*), *Fusarium cerealis* (synonym with *Fusarium crokwellense*), or *Fusarium venenatum*.

In a particular embodiment of the invention the host cell is a protease deficient or protease minus strain.  
30

This may for instance be the protease deficient strain *Aspergillus oryzae* JaL 125 having the alkaline protease gene named "alp" deleted. This strain is described in WO 97/35956 (Novo Nordisk).

Filamentous fungi cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se. The use of *Aspergillus* as a host micro-organism is described in EP 238 023 (Novo Nordisk A/S), the contents of which are hereby incorporated by reference.

#### **Production of cutinase variant by cultivation of transformant**

The invention relates, *inter alia*, to a method of producing a cutinase variant of the invention, which method comprises cultivating a host cell under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the cutinase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. as described in catalogues of the American Type Culture Collection).

The cutinase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

#### **Expression of variant in plants**

The present invention also relates to a transgenic plant, plant part or plant cell which has been transformed with a DNA sequence encoding the variant of the invention so as to express and produce this enzyme in recoverable quantities. The enzyme may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the recombinant enzyme may be used as such.

The transgenic plant can be dicotyledonous or monocotyledonous, for short a dicot. or a monocot. Examples of monocot plants are grasses, such as meadow grass (blue grass, *Poa*), forage grass such as *festuca*, *lolium*, temperate grass, such



as *Agrostis*, and cereals, e.g. wheat, oats, rye, barley, rice, sorghum and maize (corn).

Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous (family *Brassicaceae*), such as cauliflower, oil seed rape and the closely related model organism *Arabidopsis thaliana*.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers. In the present context, also specific plant tissues, such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes and cytoplasm are considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part.

Also included within the scope of the invention are the progeny of such plants, plant parts and plant cells.

The transgenic plant or plant cell expressing the variant of the invention may be constructed in accordance with methods known in the art. In short the plant or plant cell is constructed by incorporating one or more expression constructs encoding the enzyme of the invention into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

Conveniently, the expression construct is a DNA construct which comprises a gene encoding the enzyme of the invention in operable association with appropriate regulatory sequences required for expression of the gene in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences is determined, eg on the basis of when, where and how the enzyme is desired to be expressed. For instance, the expression of the gene encoding the enzyme of the invention may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are eg described by Tague et al, *Plant, Phys.*, 86, 506, 1988.

For constitutive expression the 35S-CaMV promoter may be used (Franck et al., 1980. *Cell* 21: 285-294). Organ-specific promoters may eg be a promoter from

storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990. Annu. Rev. Genet. 24: 275-303), or from metabolic sink tissues such as meristems (Ito et al., 1994. Plant Mol. Biol. 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin or albumin promoter from rice (Wu et al., Plant and Cell Physiology Vol. 39, No. 8 pp. 885-889 (1998)), a *Vicia faba* promoter from the legumin B4 and the unknown seed protein gene from *Vicia faba* described by Conrad U. et al, Journal of Plant Physiology Vol. 152, No. 6 pp. 708-711 (1998), a promoter from a seed oil body protein (Chen et al., Plant and cell physiology vol. 39, No. 9 pp. 935-941 (1998)), the storage protein napA promoter from Brassica napus, or any other seed specific promoter known in the art, eg as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the rbcS promoter from rice or tomato (Kyoizuka et al., Plant Physiology Vol. 102, No. 3 pp. 991-1000 (1993)), the chloroella virus adenine methyltransferase gene promoter (Mittra, A. and Higgins, DW, Plant Molecular Biology Vol. 26, No. 1 pp. 85-93 (1994)), or the aldP gene promoter from rice (Kagaya et al., Molecular and General Genetics Vol. 248, No. 6 pp. 668-674 (1995)), or a wound inducible promoter such as the potato pin2 promoter (Xu et al, Plant Molecular Biology Vol. 22, No. 4 pp. 573-588 (1993)).

A promoter enhancer element may be used to achieve higher expression of the enzyme in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding the enzyme. For instance, Xu et al. *op cit* disclose the use of the first intron of the rice actin 1 gene to enhance expression.

The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.

The DNA construct is incorporated into the plant genome according to conventional techniques known in the art, including *Agrobacterium*-mediated transformation, virus-mediated transformation, micro injection, particle bombardment, biolistic transformation, and electroporation (Gasser et al, Science, 244, 1293; Potrykus, Bio/Techn. 8, 535, 1990; Shimamoto et al, Nature, 338, 274, 1989).

Presently, *Agrobacterium tumefaciens* mediated gene transfer is the method of choice for generating transgenic dicots (for review Hooykas & Schilperoort, 1992. Plant Mol. Biol. 19: 15-38), however it can also be used for transforming monocots, although other transformation methods are generally preferred for these plants.

Presently, the method of choice for generating transgenic monocots is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992. Plant J. 2: 275-281; Shimamoto, 1994. Curr. Opin. Biotechnol. 5: 158-162; Vasil et al., 1992. Bio/Technology 5 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh S, et al., Plant Molecular biology Vol. 21, No. 3 pp. 415-428 (1993).

Following transformation, the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods 10 well-known in the art.

## MATERIALS AND METHODS

### Strains and plasmids

*E.coli* DH12S (available from Gibco BRL) is used for yeast plasmid rescue.

*E.coli* JM110 (available from Toyobo K.K., Japan) is used for preparing re- 15 combinant plasmids.

pJSO026 is a *S. cerevisiae* expression plasmid described in WO 97/07205 and in J.S.Okkels, (1996) "A URA3-promoter deletion in a pYES vector increases the expression level of a fungal lipase in *Saccharomyces cerevisiae*. Recombinant DNA Biotechnology III: The Integration of Biological and Engineering Sciences, vol. 782 of 20 the Annals of the New York Academy of Sciences).

pJC039 is a yeast and *E.coli* shuttle vector for expression of the "reference" cutinase variant described in the Examples under the control of TPI promoter, constructed from pJSO026.

*Saccharomyces cerevisiae* YNG318: MATa Dpep4[cir+] ura3-52, leu2-D2, 25 his 4-539 is used for the construction of yeast library and the expression of *H. insolens* cutinase. It is described in J. Biol. Chem. 272 (15), 9720-9727, 1997.

### Media and substrates

#### SC-glucose

100 ml/L	20% glucose
4 ml/L	5% threonine

10 ml/L	1% tryptophan
25 ml/L	20% casamino acids
100 ml/L	10 X basal solution
	Filter sterilized separately

10X Basal solution

66.8 g/L	yeast nitrogen base w/o amino acids
100 g/L	succinate
60 g/L	NaOH

YPD

20 g/L	Bacto pepton
10 g/L	yeast extract
100 ml/L	20% glucose (sterilized separately)

BETEB

Terephthalic acid bis(2-hydroxyethyl)ester dibenzoate is herein abbreviated  
 5 as BETEB (benzoyl-ethylene-terephthalic-ethylene-benzoate). It was prepared from  
 terephthalic acid bis (2-hydroxyethyl) ester and benzoic acid.

BETEB plate

100 ml/l	500 mM glycine buffer (pH 8.5)
1 g/l	BETEB (soluble in ethanol)
30 g/l	agar

PEG/LiAc solution

50ml	40% PEG4000 (sterile)
1ml	5M LiAc (sterile)

General primers for amplification and sequencing

10            620AM34        GAGTACTATCTTGCATTTGTAC            TAG-  
               GAGTTTAGTGAACCTTGC  
               680AM35        ATGGTTATGGATTTCTGGGGATTCTC  
               TTCGAGCGTCCCAAACCC  
               AM34            TAGGAGTTTAGTGAACCTTGC  
 15            AM35            TTCGAGCGTCCCAAACCC

18

300F CCAACGGCCTTAAGTCCCAC  
 500F GCTCATCGCTGCCGCCGTC  
 5030F GTTCTTCACCACCATCCTCAG  
 620 GAGTACTATCTTGCATTTGTAC  
 5 680 ATGGTTATGGATTTCTGGGGATTC

Primers for doped library construction

1)

Degenerated primer 47k-1

5' CTG GAT CCA GAT GTT CCG K58 787 775 68(15) W57 S66 788 K76  
 10 K57 W76 M77 GCC S56 S78 K58 GCC 658 788 S66 W77 CTC S78 568 GCC GCG  
 AGC 555 GAT CAG GAT GGC GTC GGG GCA

Dege1F (18mer)

TCTGGATCCAGGGCGTCG

Nucleotide mixture for 47k-1

15 5 96%A 2%C 2%G 2%T 6 96%C 2%A 2%G 2%T 7 96%G  
 2%C 2%A 2%T 8 96%T 2%C 2%G 2%A  
 9 94%C 3%G 3%A 10 94%A 3%G 3%C 11 94%G  
 3%C 3%A 12 94%C 6%T  
 13 94%G 3%C 3%T 14 94%G 6%A 15 94%T 3%C 3%G  
 20 16 94%C 3%G 3%T

2)

Dop83-2: (for G59-Q71 mutagenesis)

5' CGG AAC ATC TGG ATC CAG GGC GTC 12T GGC CCT TAC 345 678  
 9C10 1112G 13C4 151617 AAC 1819T 202122 CCG CGG GGC ACC TCG CAG  
 25 GCC AAC 3'

Dop2-R (16mer)

GACGCCCTGGATCCAG

Nucleotide mixture for Dop83-2

1: G 91%, A 9 % 2: G 96%, C 4% 3: G 92.5%, A 7.5%  
 30 4: A 96%, C 4% 5: G 0.5%, A 3.5%, T 96% 6: G 96%, A 2%, T  
 2%  
 7: A 4.5%, C 95.5% 8: A 2.5%, T 97.5% 9: G 92%, A 2.5%, T  
 3%, C 2.5%

19

10: G 71.5%, A 1 %, T 27.5%    11: G 3.5%, A 2%, T 43%, C 51.5%    12: T 93.5%, C 6.5%

13: G 92%, A 2.5%, T 3%, C 2.5%    14: G 71.5%, T 27.5%, A 1%    15: A 98%, C 2%

5    16: G 2.5%, T 4.5%, C 93%    17: G 54.5%, A 9.5%, T 36%    18: G 2%, A 3.5%, T 94.5%

19: A 4%, T 91%, C 5%    20: G 4.5%, T 95.5%    21: T 95.5%, C 4.5 %

22: G 98%, A 2%

3)

10    Dop83-3

5' TAC AGC CAG GGC GCC GCG CTC ATC GCT GCC GCC GTC 1C2 345  
6T7 89T 101112 13C14 151617 AAG GAG CAG GTC AAG GGC GTC 3'

Dop3-R (16mer)

AGCGATGAGCGCCGCG

15    Nucleotide mixture for Dop83-3

1: A 4.5%, T 91 %, C 4.5%    2: G 82%, A 15.5%, T 2.5%    3: G 91.5%, C 8.5%

4: A 96%, C 4%    5: G 98.5%, A 1.5%    6: T 24%, C 76%

7: G 91%, A 9%    8: A 7%, T 93%    9: A 7%, C 93%

20    10: G 94%, A 6 %    11: G 96%, A 2%, C 2%    12: G 2.5%, T 97.5%

13: G 92%, A 3%, T 2.5%, C 2.5%    14: G 6%, A 25%, T 69%    15: G 93.5%, A 6.5%

16: T 95.5%, C 4.5%    17: A 8.5%, T 91.5%

4)

25    Dop039-4

TCCTGAACTTGTTGCCCGG

VNN VNN 67T 895 (10)(11)(12) (22)(14)(15) (16)A(17) 67T CTT (18)A8 3CR  
G7A (19)(20)T (24)(21)(17) (19)(10)T 8(22)(23)

TGCCCCGACGCCATCCTG

30    039-4-R(20mer)

CCGGGCAACAAGTTCAGGAG

5)

Dop039-5

20  
 GACGCCGCGCTGGCCACC 1NT 233 CTG CCG 455  
 GGCACCTCGCAGGCCAAC  
 039-5-R (18mer)  
 GGTGGCCAGCGCGGCGTC  
 5 6)  
 Dop039-6  
 ACACCCAAAACCTCCAG  
 (10)(10)(17) (19)(32)8 6(32)(25) 6(33)T (34)T(12) (24)9(35) aac-  
 taccgcgcgagcgc  
 10 039-6-R (20mer)  
 CTGGAGGTTTTGGGTGTATC  
 7)  
 Dop039-7  
 CTGCAACGTTGGCGAC  
 15 8(24)(25) 8(26)(17) TGC (19)9(23) 67T (19)(27)(23) (28)(11)R (19)(29)(12)  
 (19)(29)3 (30)(31)(23) (24)(27)5 8(21)(12) CAT (24)(13)(23)  
 AGTTACACTATTCAGGCG  
 039-7-R (19mer)  
 GTCGCCAACGTTGCAGAAC  
 20 Nucleotide mixture for Dop039-4,5,6,and 7  
 1 G20, A70, C10  
 2 A10, T65, C25  
 3 A20, T80  
 4 A66, T10, C24  
 25 5 G60, A20, T20  
 6 G95, A5  
 7 G95, C5  
 8 G94, A3, T3  
 9 T5, C95  
 30 10 G3, A94, C3  
 11 G3, T94, C3  
 12 A5, T95  
 13 A2, T96, C2

	14	A96, T4
	15	G36, A62, T2
	16	A92, T4, C4
	17	G4, A4, T92
5	18	G97, T1, C2
	19	G4, A96
	20	G91, A3, T3, C3
	21	A4, C96
	22	G2, A2, C94
10	23	G10, A40, T50
	24	G2, A2, T2, C94
	25	G24, A6, T70
	26	T94, C6
	27	G6, C94
15	28	G5, A2, T36, C56
	29	G3, A3, T91, C3
	30	G5, A93, T2
	31	A3, T3, C94
	32	G80, A10, C10
20	33	G80, T7, C13
	34	G15, A70, C15
	35	G12, A65, T23

Primers for spiked library construction

25	Spike 1
	Cu-1-44-1:
	5'- GTCGGCCCTGCTCTCGCC <b>WC</b> AGGCCTTAAGTCCCACATCCC
	Cu-1-44-2:
	5'- GTCGGCCCTGCTCTCGCC <b>ST</b> GGGCCTTAAGTCCCACATCCC
30	Cu-1-44-3:
	5'- GTCGGCCCTGCTCTCGCC <b>CA</b> AGGCCTTAAGTCCCACATCCC
	Cu-1-46:
	5'- CCTGCTCTCGCC <b>AA</b> CGGCWTTAAGTCCCACATCCCGAACAT



Cu-1-48:  
5'- CTCTCGCCAACGGCCTTAAGNANCACATCCCGAACATCTGGAT  
Cu-1-48-T:  
5'- CTCTCGCCAACGGCCTTAAGACACACATCCCGAACATCTGGAT  
5  
Cu-1-51-1:  
5'- ACGGCCTTAAGTCCCACATCNANAACATCTGGATCCAGGGCGT  
Cu-1-51-2:  
5'- ACGGCCTTAAGTCCCACATCWCAAACATCTGGATCCAGGGCGT  
Cu-1-55-1: antisense:  
10 5'- GGGCCGCCGACGCCCTGGTWCCAGATGTTCTGGGATGTGGG  
Cu-1-55-2: antisense:  
5'- GGGCCGCCGACGCCCTGNAMCCAGATGTTCTGGGATGTGGG  
Spike2  
Cu-2-48:  
15 5'- CTCTCGCCAACGGCCTTAAGVNNCACATCCCGAACATCTGGAT  
Cu-2-66:  
5'- GCCCTTACGACGCCGCGVNNGCCACCAACTTCCTGCCG  
Cu-2-88:  
5'- ACGAGGGCAAGCGGCTGTTTVNNCTGGCCAACCAAAAGTGCCC  
20 Cu-2-91:  
5'- CGGCTGTTTGCGCTGGCCVNNCAAAAGTGCCCCAACACGCC  
Cu-2-88-91:  
5'- ACGAGGGCAAGCGGCTGTTTVNNCTGGCCVNNCAAAAGTGCCC-  
CAACACGCC  
25 Cu-2-119:  
5'- CCGCCGTCAGCGAGCTCVNNGGCGCCGTCAAGGAGCAG  
Cu-2-169:  
5'- CTGCACCGGCACGCTCATCVNNACCCCGGCGCATCTGAGTTA  
Cu-2-189:  
30 5'- GTGAAGCCGCGCGTTTTCTAVNNGATCGGATAAGGGCTTAATC  
Spike3  
Cu-3-29:  
5'- TGATCTTTGCTCGCGGCTCGVNNAGCCAGGCAACATGGGCAT

Cu-3-70:

5'- CCGCGCTGGCCACCAACVNNCTGCCGCGGGGCACCTC

Cu-3-66-70:

5'- GCCCTTACGACGCCGCGVNNGCCACCAACVNNCTGCCGCGGGG-

5 CACCTC

Cu-3-139:

5'- TCGGATACACCCAAAACCTCVNNAACCGTGGCGGCATCCCCA

Cu-3-167:

5'-CCGTCTGCACCGGCACGVNNATCATCACCCCGGCGCATCT

10

Cu-3-168:

5'-TCTGCACCGGCACGCTCVNNATCACCCCGGCGCATCTGA

Cu-3-167+168:

5'-CCGTCTGCACCGGCACGVNNVNNATCACCCCGGCGCATCTGA

Cu-3-167+169:

15

5'-CCGTCTGCACCGGCACGVNNATCVNNACCCCGGCGCATCTGAGTTA

Cu-3-168+169:

5'-TCTGCACCGGCACGCTCVNNVNNACCCCGGCGCATCTGAGTTA

Cu-3-174:

5'- TCATCATCACCCCGGCGCATVNNAGTTAACTATTCAAGGCGAG

20

Cu-3-167+174:

5'-

CCGTCTGCACCGGCACGVNNATCATCACCCCGGCGCATVNNAGTTAACTATT-  
CAGGCGAG

Cu-3-168+174:

25

5'-

TCTGCACCGGCACGCTCVNNATCACCCCGGCGCATVNNAGTTAACTATT-  
CAGGCGAG

Cu-3-169+174:

5'-

30 CTGCACCGGCACGCTCATCVNNACCCCGGCGCATVNNAGTTAACTATT-  
CAGGCGAG

Spike4

Cu4-4: 5'- TTGTTGCCCCGGCAGCTGGGAVNNATCCAGAACGGCCTTGA-  
GAG

Cu4-5: 5'- TTGCCCCGGCAGCTGGGAGCCVNN CAGAACGGCCTTGA-  
GAGCGG

5 Cu4-6: 5'- CCCGGCAGCTGGGAGCCATCVNN AACGGCCTTGA-  
GAGCGGCAG

Cu4-4+5: 5'- TTGTTGCCCCGGCAGCTGGGAVNNVNNCAGAACGGCCTT-  
GAGAGCGG

Cu4-4+6: 5'- TTGTTGCCCCGGCAGCTGGGAVNNATCVNN  
10 AACGGCCTTGAAGCGGCAG

Cu4-5+6: 5'- TTGCCCCGGCAGCTGGGAGCCVNNVNN AACGGCCTTGA-  
GAGCGGCAG

Cu4-33: 5'- GCGGCTCGACCGAGCCAGGC VNN ATGGGCAT-  
CACCGTCGGCCC

15 Cu4-34: 5'- GCTCGACCGAGCCAGGCAAC VNN GGCAT-  
CACCGTCGGCCCTGC

Cu4-33+34: 5'- GCGGCTCGACCGAGCCAGGC VNN VNNGGCAT-  
CACCGTCGGCCCTGC

Spike5

20 Cu5-7: 5'- GGCAGCTGGGAGCCATCCAG VNN GGCCTTGA-  
GAGCGGCAGCCC

Cu5-8: 5'- AGCTGGGAGCCATCCAGAAC VNN CTTGA-  
GAGCGGCAGCCCCAA

Cu5-9: 5'- TGGGAGCCATCCAGAACGGC VNN GA-  
25 GAGCGGCAGCCCCAACGC

Cu5-55: 5'- CCCACATCCCGAACATCTGG VNN  
CAGGGCGTCGGCGGCCCTTA

Cu5-56: 5'- ACATCCCGAACATCTGGATC VNN  
GGCGTCGGCGGCCCTTACGA

30 Cu5-57: 5'- CGAACATCTGGATCCAGGGC VNN  
GGCGGCCCTTACGACGCCGC

Cu5-55+56: 5'- CCCACATCCCGAACATCTGG VNN VNN  
GGCGTCGGCGGCCCTTACGA

Cu5-

55+57:5'cCCACATCCCGAACATCTGGVNNGGCVNNGGCGGCCCTTACGACGCC  
GC

Cu5-56+57: 5'- ACATCCCGAACATCTGGATC VNN VNN

5 GGCGGCCCTTACGACGCCGC

2<sup>nd</sup> round spike

G120D (39mer)

GCCGTCAGCGAGCTCAGCGACGCCGTCAAGGAGCAGGTC

Q1CL2V (42mer)

10 CCTGAACTTGTTGCCCCGGTGTGTCTGGAGCCATCCAGAACGGC

N44D F (39mer)

GTCGGCCCTGCTCTCGCCGACGGCCTTAAGTCCCACATC

A130V(39mer)

GAGCAGGTCAAGGGCGTCGTCCTCTTCGGATACACCCAA

15 S48EK (39mer)

CTCGCCAACGGCCTTAAGRAGCACATCCCGAACATCTGG

I169G (39mer)

TGCACCGGCACGCTCATCGGTACCCCGGCGCATCTGAGT

R189H (39mer)

20 GAAGCCGCGCGTTTTCTACACGATCGGATAAGGGCTTAA

R189V (39mer)

GAAGCCGCGCGTTTTCTAGTGGATCGGATAAGGGCTTAA

L174F(39mer)

ATCATCACCCCGGCGCATTTTAGTTACACTATTCAGGCG

25 H49Y(39mer)

GCCAACGGCCTTAAGTCCTACATCCCGAACATCTGGATC

A88H(39mer)

GAGGGCAAGCGGCTGTTTCACCTGGCCAACCAAAAGTGC

N91H(39mer)

30 CGGCTGTTTGCGCTGGCCCAACCAAAAGTGCCCCAACACG

Q1LL2K (42mer)

CCTGAACTTGTTGCCCCGGCTGAAGGGAGCCATCCAGAACGGC

G8D (39mer)

CTGGGAGCCATCCAGAACGATCTTGAGAGCGGCAGCCCC

N15D (42mer)

CTTGAGAGCGGCAGCCCCGATGCGTGCCCCGACGCCATCCTG

## Methods

### 5 Lipase activity (LU)

A substrate for lipase is prepared by emulsifying tributyrin (glycerin tributyrate) using gum Arabic as emulsifier. The hydrolysis of tributyrin at 30 °C at pH 7 is followed in a pH-stat titration experiment. One unit of lipase activity (1 LU) equals the amount of enzyme capable of releasing 1 µmol butyric acid/min at the standard

10 conditions.

### Primary screening method

1. Spread yeast library onto SC-glucose plates and incubate for 3 days at 30°C.
2. Replica to new SC-glucose plates with nitrate filters by using velvet cloth.
- 15 Incubate the plates at 30°C for 1 days. (or 20°C O/W)
3. Transfer the filters to pre-heated 0.1% BETEB plates (pH8.5) with/without 50ppm Avolan.
4. Incubate BETEB plate with Avolan at 70°C and w/o Avolan at 73°C O/N.
5. Remove the filters and find the yeast clones with clear zones.
- 20 6. Isolate candidate clones from the master plate and inoculate to a new SC-glucose plate and 1ml of YPD medium in 24well plates.

### Secondary screening method

1. Cultivate YPD medium in 24well plates at 30°C for 2 days at 180rpm.
2. Centrifuge the plate/ or just leave them still for a few hours.
- 25 3. Apply 5µl and 10µl of supernatants to holes in a BETEB plates with Avolan and 2 without Avolan.
4. Incubate one BETEB plate and the BETEB plate with Avolan at 60°C, the other BETEB plate at 68°C overnight.
5. Check the diameter of clear zones.
- 30 6. Determine the LU activity of the supernatant of the clones which retains activity at 68°C or 60°C with Avolan.

7. Adjust the LU activity to 10LU/ml and apply to BETEB plates as 4).
8. Check the diameter of clear zones.

#### Method for construction of yeast library

1. Mix 0.5µl of vector (Hind III-Xba I digested) and 1µl of PCR fragments.
- 5 2. Thaw YNG318 competent cell on ice.
3. Mix 100µl of the cell, the DNA mixture and 10µl of carrier DNA (Clontech) in Falcon 1058.
4. Add 0.6ml PEG/LiAc solution and mix gently.
5. Incubate at 30°C at 200 rpm for 30min.
- 10 6. Incubate at 42°C for 15 min (heat shock).
7. Transfer to a eppendorf tube and centrifuge for 5sec.
8. Remove the supernatant and resolve in 3ml of YPD.
9. Incubate the cell suspension for 45min at 30rpm at 30°C.
10. Pour the suspension to SC-glucose plates to give ca.300clones/plate.

#### 15 Library construction

Dop libraries are constructed by SOE method followed by yeast recombination.

#### Other methods

- *E.coli* transformation for constructing libraries and subcloning is carried  
20 out by electroporation (BIO-RAD Gene Pulser).
- DNA Plasmids are prepared by alkaline method (Molecular Cloning, Cold Spring Harbor) or with the Qiagen® Plasmid Kit.
- DNA fragments are recovered from agarose gel by the Qiagen gel extraction Kit.
- 25 ▪ PCR is carried out by the PTC-200 DNA Engine
- The ABI PRISM™ 310 Genetic Analyzer is used for determination of all DNA sequences.
- Yeast transformation is carried out by lithium acetate method.
- Yeast total DNA is extracted by the Robzyk and Kassir's method de-  
30 scribed in Nucleic acids research vol.20, No14 (1992) 3790.
- All positive clones in the secondary assay are cultivated in 1 ml of YPD at 30° C overnight for extracting total yeast DNA. The prepared DNA is introduced into

*E.coli*, isolate *E.coli* colonies and prepare their plasmids for sequencing and further evaluation.

## EXAMPLES

### Example 1: Construction of cutinase variants by doping

- 5 The first PCR reaction was carried out with 2 primer pairs, 620AM34 and Dop2R, and Dop83-2 and 680AM35 under the following condition:

48.6 µl	H <sub>2</sub> O
33 µl	3.3 X reaction buffer
4.4 µl	25 mM MgOAc
2 µl	<i>rTth</i> polymerase (Perkin Elmer)
8 µl	10 mM dNTPs
1 µl X 2	100 pmol/µl Primers
1 µl	0.5 µg/µl Template (pJC039)

1	94° C	20 sec
2	94° C	15 sec
3	45° C	45 sec
	72° C	30 sec + 3 sec/cycle
	2-4	50 cycles
5	72° C	10 min

- The resulting fragments were gel-purified and used for the template for the second PCR reaction. The second PCR was carried out with 620 and 680 as prim-  
10 ers under the following condition.

38.2 µl	H <sub>2</sub> O
5 µl	10 X reaction buffer
1 µl	<i>Klen Taq LA</i> (CLONTECH)
4 µl	10 mM dNTPs
0.4µl X 2	100 pmol/µl Primers
0.5µl X 2	PCR fragments

1	98° C	10 sec
2	68° C	90 sec
1-2	30 cycles	
3	68° C	10min

#### Spiked oligo shuffling library

Spiked libraries were constructed as follows:

PCR reaction for preparing a gene fragment of the reference variant described in a later example was carried out with *rTth* polymerase and AM34 and 5 AM35 as primers as described above and the fragment was gel-purified.

About 10 ug DNA/250µl was incubated with 0.8µl DNaseI (Gibco BRL 18068-015) and 30µl 10X buffer at 25°C for 7-10min. Adding EDTA to the final concentration at 10mM stopped the reaction.

DNA fragments of correct size (50-150bp) was purified by Whatman glass filter.

Then the DNase treated fragments were reassembled under the following condition.

0.2, 0.5 and 1 pmol	DNase-treated template
3, 6, 12x molar	excess of each mutagenic oligo
1 beads	Ready-to-go
0.1µl	<i>Pwo</i> polymerase
final volume 25µl	

1	94°C	2 min.
2	94°C	30 sec
3	45°C	30 sec
4	72°C	1 min.:
2-4	30 cycles	
5	72°C	5 min.

Using the above PCR mixture as a template, second PCR was carried out under the following condition:

0.2, 0.5, 1 and 2µl	1 <sup>st</sup> PCR reaction
2 beads	Ready-to-go
0.3µl	100pmol primer 1 (AM34)



30

0.3µl	100pmol primer 2 (AM35)
0.1µl	Pwo polymerase

1	94°C	2 min.
2	94°C	30 sec
3	55°C	30 sec
4	72°C	90 sec
2-4	25cycles	
5	72°C	10 min.

### Example 2: Thermostability of variants

A number of samples were prepared, each containing 10 LU/ml of a variant of the *H. insolens* cutinase. 20 µl of each sample was applied to a well of a BETEB plate, and the plate was incubated at 68° overnight (14 hours). The presence of a clearing zone around the well was taken as a positive result.

The following variants according to the invention were tested, and a reference variant (not according to the invention) was included for comparison.

Reference	E6Q +A14P +E47K +R51P +E179Q
Invention	Reference +S48E +A88H +N91H +R189V
	Reference +(AAVDSNHTPAVPELVAR) +Q1L +L2K +G8D +N15D
	Reference +N44D +A130V
	Reference +Q1C +L2V +G120D
	Reference +A88L +R189A
	Reference +S48E +L66I +A88L +I169A +R189H
	Reference +A88V +S116K +S119P +Q139R +I169V +R189V
	Reference +A88V +R189A
	Reference +S48K +A88H +I169G +R189H
	Reference +Q1L +L2Q +A4V +S11T
	Reference +T164S
	Reference +L174F
	Reference +H49Y

	Reference +(AAVDSNHTPAVPELVAR) +Q1L +L2K +G8D +N15D +S48E +A88H +N91H +R189V
	Reference +(AAVDSNHTPAVPELVAR) +Q1L +L2K +G8D +N15D +N44D +A130V
	Reference +(AAVDSNHTPAVPELVAR) +Q1L +L2K +G8D +N15D +N44D +S48E +A88H +N91H +A130V +R189V
	Reference +G8D +N15D +A16T
	Reference +A130V
	Reference +Q1C +L2V

As indicated above, each variant contained the same substitutions as the reference variant (E6Q +A14P +E47K +R51P +E179Q) and additionally one or more substitutions according to the invention. As shown above, four variants are believed to have an N-terminal extension stemming from the substitution A(-7)V in the prosequence resulting in an alteration of the cleavage site.

The results were that all variants of the invention showed a distinct clearing zone whereas the reference did not. The reference variant showed a clearing zone in a similar experiment at 60°C. Thus, each set of substitutions according to the invention markedly improved the thermostability of the variant.

Some variants were also tested at higher temperatures, and some of the above variants gave positive results at temperatures as high as 76 °C.

### Example 3: Stability of variants in presence of detergent

Cutinase variants were incubated with anionic surfactant (10 or 40 ppm of Avolan, product of Bayer) at 60°C, and the residual activity was determined after 14 hours. 8 of the variants described in the previous example were found to have significant residual activity after incuation with 10 ppm of detergent and some activity with 40 ppm. The reference variant showed no residual activity.

### Example 4: Thermostability by DSC

Thermostability of cutinase variants was investigated by means of DSC at pH 10 (50 mM glycine buffer). The thermal denaturation temperature, T<sub>d</sub>, was taken as the top of denaturation peak (major endo-thermic peak) in thermograms (C<sub>p</sub> vs.

T) obtained after heating of enzyme solutions at a constant programmed heating rate.

The reference variant described above was found to have Td of 68°C. Three variants according to the invention described in Example 2 were found to have Td of 5 71-72°C, i.e. a clear improvement.

**CLAIMS**

1. A variant of a parent fungal cutinase, which variant:
  - a) comprises substitution of at least one amino acid residue corresponding to position G8, A88, N91, A130, Q139, I169 or R189 in the cutinase of *Humicola insolens* strain DSM 1800 (*H. insolens* cutinase numbering), and
  - b) is more thermostable than the parent cutinase.
2. The variant of the preceding claim which comprises the substitution G8D, A88H/L/V, N91H, A130V, Q139R, I169V or R189A/H/V.
3. A variant of a parent fungal cutinase, which variant:
  - a) comprises substitution of at least one amino acid residue corresponding to Q1C/L, L2K/Q/V, A4V, S11T, N15D, A16T, S48E/K, H49Y, L66I, S116K, S119P, G120D, T164S, I169A/G/V in the cutinase of *Humicola insolens* strain DSM 1800 (*H. insolens* cutinase numbering), and
  - b) is more thermostable than the parent cutinase.
4. The variant of any preceding claim wherein the parent cutinase:
  - a) is native to a filamentous fungus, particularly a strain of *Humicola* or *Fusarium*, particularly *H. insolens* or *F. solani pisi*, most particularly *H. insolens* strain DSM 1800,
  - b) has an amino acid sequence which can be aligned with the cutinase of *H. insolens* strain DSM 1800, or
  - c) has an amino acid sequence which is at least 50 % homologous to the cutinase of *H. insolens* strain DSM 1800, particularly at least 70 % homologous, more particularly at least 80 % homologous.
5. A variant of the cutinase of *Humicola insolens* strain DSM 1800, which variant:
  - a) comprises a substitution of amino acid residue N44 or L174, and
  - b) is more thermostable than the parent cutinase.

6. The variant of the preceding claim which comprises the substitution N44D or L174F.

7. The variant of any preceding claim which has one to twenty of such substitutions, particularly 2-15.

5 8. The variant of any preceding claim comprising substitutions corresponding to:

- a) S48E +A88H +N91H +R189V
- b) Q1L +L2K +G8D +N15D
- c) N44D +A130V
- d) Q1C +L2V +G120D
- 10 e) A88L +R189A
- f) S48E +L66I +A88L +I169A +R189H
- g) A88V +S116K +S119P +Q139R +I169V +R189V
- h) A88V +R189A
- i) S48K +A88H +I169G +R189H
- 15 j) Q1L +L2Q +A4V +S11T
- k) T164S
- l) L174F
- m) H49Y
- n) Q1L +L2K +G8D +N15D +S48E +A88H +N91H +R189V
- 20 o) Q1L +L2K +G8D +N15D +N44D +A130V
- p) Q1L +L2K +G8D +N15D +S48E +A88H +N91H +A130V +R189V
- q) G8D +N15D +A16T
- r) A130V
- s) Q1C +L2V and/or
- 25 t) G8D +N15D +A16T.

9. The variant of any preceding claim which further comprises at least one amino acid substitution at positions corresponding to Q1, L2, E6, E10, S11, A14, N15, F24, L46, E47, R51, D63, L138 and/or E179 (*H. insolens* cutinase numbering).

10. The variant of the preceding claim comprising at least one substitution corresponding to Q1P, L2V, E6Q, E10Q, S11C, A14P, N15T, F24Y, L46I, E47K, R51P, D63N, L138I and/or E179Q (*H. insolens* cutinase numbering).

11. The variant of the preceding claim comprising substitutions corresponding to  
5 E6Q +A14P +E47K +R51P +E179Q.

12. The variant of any preceding claim which has hydrolytic activity towards terephthalic acid esters, particularly towards cyclic tri(ethylene terephthalate) and/or Terephthalic acid bis(2-hydroxyethyl)ester dibenzoate (BETEB).

13. The variant of any preceding claim which has a denaturation temperature which  
10 is at least 5° higher than the parent cutinase, particularly measured at pH 8.5.

14. A DNA sequence encoding the variant of any preceding claim.

15. A vector comprising the DNA sequence of the preceding claim.

16. A transformed host cell harboring the DNA sequence of claim 14 or the vector of claim 15.

15 17. A method of producing the variant of any of claims 1-13 comprising  
a) cultivating the cell of claim 16 so as to express and optionally secrete the variant, and  
b) recovering the variant.

18. A method of producing a cutinase variant, which method comprises:

20 a) selecting a parent fungal cutinase,  
b) altering at least one amino acid residue in the parent cutinase substitution, deletion or insertion at a position corresponding to A4, G8, N44, S48, H49, L66, A88, N91, S116, S119, G120, A130, Q139, T164, I169, L174 or R189 or in a region comprising such position in the *H. insolens* cutinase  
25 (*H. insolens* cutinase numbering) and optionally at other positions to obtain a variant cutinase,

- c) testing the thermostability of the variant cutinase,
- d) optionally repeating steps b-c,
- e) selecting a variant cutinase having higher thermostability than the parent cutinase, and
- 5 f) producing the selected variant cutinase.

19. The method of claim 18 wherein the amino acid alteration is done by localized random mutagenesis in a region comprising at least one of the indicated positions.

20. The method of claim 18 wherein the amino acid alteration is done by point specific mutation in at least one of the indicated positions, particularly by substitution at  
10 one, two, three, four, five or six of said positions.

21. The method of any preceding claim wherein the selected variant cutinase has a denaturation temperature which is at least 5° higher than the parent cutinase, particularly measured at pH 8.5.

22. The method of any preceding claim wherein the parent cutinase:

- 15 a) is native to a filamentous fungus, particularly a strain of *Humicola* or *Fusarium*, particularly *H. insolens* or *F. solani pisi*, most particularly *H. insolens* strain DSM 1800,
- b) has an amino acid sequence which can be aligned with the cutinase of *H. insolens* strain DSM 1800, or
- 20 c) has an amino acid sequence which is at least 50 % homologous to the cutinase of *H. insolens* strain DSM 1800, particularly at least 70 % homologous, more particularly at least 80 % homologous.

23. A process for enzymatic hydrolysis of a cyclic oligomer of poly(ethylene terephthalate), which process comprises treating the cyclic oligomer with a variant of a parent  
25 fungal cutinase, which variant comprises substitution of one or more amino acid residues at a position corresponding to A4, G8, N44, S48, H49, L66, A88, N91, S116, S119, G120, A130, Q139, T164, I169, L174 or R189 in the *H. insolens* cutinase (*H. insolens* cutinase numbering).

24. The process of the preceding claim, in which the cyclic oligomer is cyclic tri(ethylene terephthalate).
25. The process of claim 23 or 24 wherein the treatment is done at 60-80°C, particularly at 65-75°C.
- 5 26. The process of any of claims 23-25 wherein the cyclic oligomer is present in and on the fibers of a polyester containing fabric or yarn.
27. The process of any of claims 23-26 which further comprises subsequently rinsing the fabric or yarn, particularly rinsing with an aqueous solution having a pH in the range of from about pH 7 to about pH 11.
- 10 28. A process for improving the functional finish of a PET-containing yarn or fabric comprising
- 15 a) treating the yarn or fabric with a variant of a parent fungal cutinase, which variant comprises substitution of one or more amino acid residues at a position corresponding to A4, G8, N44, S48, H49, L66, A88, N91, S116, S119, G120, A130, Q139, T164, I169, L174 or R189 in the *H. insolens* cutinase (*H. insolens* cutinase numbering), and
- b) subsequently treating the yarn or fabric with a finishing agent selected from the group consisting of softeners, anti-crease resins, anti-static agents, anti-soiling agents.
- 20 29. A process for dyeing polyester fabric or yarn, comprising:
- a) treating the fabric or yarn with a cutinase having a thermal denaturation temperature of 65°C or higher at pH 8.5; and
- b) dyeing the treated fabric with a reactive dye or a disperse dye.
30. The process of the preceding claim wherein the cutinase is a variant of a parent
- 25 fungal cutinase, which variant comprises substitution of one or more amino acid residues at a position corresponding to A4, G8, N44, S48, H49, L66, A88, N91, S116, S119, G120, A130, Q139, T164, I169, L174 or R189 in the *H. insolens* cutinase (*H. insolens* cutinase numbering).



31. A detergent composition comprising a surfactant and the variant of any of claims 1-13.

32. A fungal cutinase having a peptide extension AAVDSNHTPAVPELVAR at the N-terminal.